



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostics.com

Date: 30-09-2026

To

The Manager

Listing Department

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex

Bandra (East), Mumbai – 400051

SYMBOL: CHANDAN

ISIN: INE0B2N01016

Subject: Proceedings of the 23rd Annual General Meeting of the Company held on September 30, 2026

We refer to our letter dated **September 7, 2026**, informing you about the Annual General Meeting ("AGM") of the Members of the Company scheduled to be held through Video Conference ("VC") / Other Audio-Visual Means ("OAVM") on **Wednesday, September 30, 2026**.

In this regard, we write to inform that the AGM was held on **Wednesday, September 30, 2026**, through VC/OAVM, in compliance with the applicable provisions of the Companies Act, 2013, the circulars issued by the Ministry of Corporate Affairs, Securities and Exchange Board of India ("SEBI") and other applicable provisions.

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the **Summary of Proceedings of the AGM** of the Company.

The meeting commenced at **04.00 P.M.** and concluded at **04.36 P.M.**

This is for your information and record.

We kindly request you to take the above submission on record.

Yours sincerely,

For Chandan Healthcare Limited

RAJEEV
NAIN

Digitally signed
by RAJEEV NAIN
Date: 2026.09.30
16:47:31 +05'30'

Rajeev Kumar Nain

Company Secretary & Compliance Officer

Enclosure: As above

SUMMARY OF PROCEEDINGS OF ANNUAL GENERAL MEETING OF CHANDAN HEALTHCARE LIMITED

The Annual General Meeting (“AGM”) of the Members of **Chandan Healthcare Limited** (“the Company”) was held on **Wednesday, September 30, 2026 at 4.00 P.M. IST**, through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”), in compliance with the applicable provisions of the Companies Act, 2013, the circulars issued by the Ministry of Corporate Affairs and SEBI Regulations.

Mr. Rajeev Nain, Chief Financial Officer and Company Secretary, welcomed the Members to the AGM and informed them about the conduct of the Meeting through VC/OAVM. He further informed that the facility for Members to join the Meeting was opened 30 minutes prior to its commencement and would remain open for 15 minutes after its conclusion.

The following Directors were present at the Meeting:

1. **Dr. Amar Singh** – Chairman-cum-Managing Director: Present
2. **Ms. Asmita Singh** – Managing Director: Present
3. **Mr. Vinay Lamba** – Non-Executive Director: Present

The Statutory Auditors, Secretarial Auditors, Cost Auditors and Internal Auditors, or their respective representatives, and Mr. Akshat Garg of M/s. Akshat Garg and Associates, Practising Company Secretaries, the Scrutinizer for the Meeting, were also in attendance.

The requisite quorum being present, **Mr. Rajeev Nain confirmed to the Chairman that the Meeting was duly convened and constituted**. Thereafter, the Chairman welcomed the Members and addressed the Meeting.

The Chairman welcomed the Members to the 23rd AGM of the Company and informed them that Financial Year 2025-26 had been a very successful year for the Company, marked by strong financial and operating growth, expansion of the diagnostic network across new states and cities, introduction of new growth channels, strengthening of institutional partnerships and securing of long-duration public-private partnership (“PPP”) projects.

The Chairman apprised the Members of the key highlights of the Company's performance and operations during FY26, including:

- **Financial Performance:** On a consolidated basis, Total Income increased by 20.43% to ₹280.67 crore (FY25: ₹233.06 crore) and Profit After Tax increased by 21.42% to ₹28.55 crore (FY25: ₹23.52 crore). On a standalone basis, Total Income increased by 22.53% to ₹160.77 crore and Profit After Tax grew by 21.96% to ₹25.34 crore;
- **Operating Metrics:** The number of tests performed increased from approximately 7.3 million to 8.8 million, and the number of diagnostic patients increased from approximately 1.7 million to 2 million;
- **Network Expansion:** The Company has an operating presence across 15 States and Union Territories, with new centres in markets such as Mumbai, Kolkata, Bengaluru, Chandigarh, Vadodara, Kota, Udaipur, Kurukshetra and Raipur. The network comprises 23 Comprehensive Diagnostic Centres, 18 Diagnostic Centres, 25 Standalone Laboratories and 2 Central Reference Laboratories, supported by a franchise network;
- **Franchise and Digital Channels:** The franchise network, which stood at 235 centres at the end of FY26, has expanded to more than 600 centres, with a target of more than 2,000 franchise

centres by the end of FY27. The Chandan 24x7 platform has crossed 3 lakh users, with approximately 10,000 users being added every month;

- **Strategic Partnership with Jeena Sikho Lifecare Limited:** Under a five-year exclusive arrangement, the Company has been appointed as the diagnostics partner for all existing and upcoming Jeena Sikho hospitals and clinics. Approximately 80% of the partner locations are operational and monthly revenue from the relationship has crossed ₹1.50 crore. Jeena Sikho Lifecare Limited also subscribed to 18 lakh warrants out of the 44.50 lakh warrants issued under the Company's preferential issue during FY26; and
- **PPP Projects:** The Company secured three 10-year radiology PPP awards in Punjab covering 12 locations (nine MRI and three CT installations), a 10-year MRI project at Civil Hospital, Rohtak, and a 10-year advanced radiology project at the Northeast Frontier Railway Central Hospital, Guwahati.

The Chairman further informed the Members that during the year the Company had acquired two Comprehensive Diagnostic Centres, one each at Delhi and Ghaziabad, and that further acquisitions were in process. By the end of FY27, the Company expects to have a presence in 16 States with 37 Comprehensive Diagnostic Centres, 48 Diagnostic Centres and 30 Standalone Laboratories, along with two Central Reference Laboratories at Lucknow, Uttar Pradesh and Haldwani, Uttarakhand.

The Chairman also informed the Members that, following the divestment of the Company's entire 53.56% shareholding in Chandan Pharmacy Limited, the Company's focus is increasingly centred on pathology, radiology and advanced diagnostics, enabling more effective deployment of capital and management bandwidth.

Outlining the growth roadmap, the Chairman stated that the Company would continue expanding its laboratory presence under its 'One District, One Lab' initiative, scale the franchise network, strengthen home sample collection and online diagnostics, deepen the Jeena Sikho partnership and commission the new centres currently under development, including a planned Genome Sequencing Laboratory at Lucknow and PET-CT centres at Kanpur and Gorakhpur. The Chairman concluded by thanking the shareholders, doctors, employees, patients, institutional partners, franchise partners and business associates for their continued trust and support.

The Members were thereafter given an opportunity to ask questions and seek clarifications in relation to the business proposed to be transacted at the AGM. The questions raised by the Members were duly addressed by the Chairman/management.

Since the AGM was conducted through VC/OAVM and the resolutions had already been put to vote through remote e-voting, there was no proposing and seconding of resolutions, and the Notice convening the AGM was taken as read.

The following items of business, as set out in the Notice of the AGM, were taken up for consideration and approval of the Members:

Item No.	Particulars of Resolution	Type of Resolution
1(a)	To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditors thereon	Ordinary Resolution
1(b)	To receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Report of the Auditors thereon	Ordinary Resolution

2	To appoint a Director in place of Mr. Amar Singh (DIN: 01096328), who retires by rotation and, being eligible, offers himself for re-appointment	Ordinary Resolution
3	To ratify the remuneration of the Cost Auditor for the financial year ending March 31, 2027	Ordinary Resolution
4	To approve variation in the objects and utilisation of the proceeds of the preferential issue of convertible warrants	Special Resolution
5	To appoint Mr. Sanjay Srivastava (DIN: 11927967) as an Independent Director of the Company	Special Resolution

The Members were informed that **Mr. Akshat Garg, Practising Company Secretary, M/s. Akshat Garg and Associates**, had been appointed as the Scrutinizer for scrutinising the remote e-voting and e-voting conducted during the AGM in a fair and transparent manner.

The consolidated results of the remote e-voting and e-voting conducted during the AGM, together with the Scrutinizer's Report, will be submitted to the Stock Exchanges and made available on the website of the Company within the prescribed timelines.

The Chairman thanked the Members, Directors and Auditors for their participation and support.

Thereafter, with the consent of the Chairman, **Mr. Rajeev Nain declared the proceedings of the AGM closed.**

The Meeting concluded at **04.36 P.M.** (including the time allowed for e-voting at the AGM).

For Chandan Healthcare Limited

RAJEEV
NAIN

Digitally signed
by RAJEEV NAIN
Date: 2026.09.30
16:49:16 +05'30'

SD/-

Rajeev Kumar Nain

Company Secretary & Compliance Officer

Membership No.: A35449